Community/Retail

Is your life how you imagined it would be, or is it, in reality, more complicated and stressful than you planned? Do you wonder how you managed to achieve all you did including all the patient contacts, and fielding the calls from doctors, too?

Lupin Pharmaceuticals, Inc. has voluntarily recalled 42 of lots of Ceftriaxone for Injection, USP products at the hospital/physician level. These products were found to contain visual grey particulate matter in reconstituted vials.

How can pharmacists implement nonpharmacologic treatments for patients with dementia?

Pharmacy Times’ Ed Cohen, PharmD, FAPha, interviews Miranda Rochol, Healthcare Product Management & Strategy Executive for IQVIA, about opportunities for pharmacy professionals utilizing the company’s services.

The FDA approved cannabidiol (CBD) last year for the treatment of seizures associated with Lennox-Gastaut and Dravet syndromes in patients aged 2 years and older. As pharmacists, we will likely be called upon as experts in CBD therapeutics.

A recall of Torrent Pharmaceuticals Limited’s Losartan Potassium Tablets USP has been expanded to include 8 additional lots. A total of 10 lots are now being recalled at the consumer level, including 2 recalled lots initially announced December 20, 2018.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Michael Ganio, Director, Pharmacy Practice and Quality for the American Society of Health-System Pharmacists addresses a shortage of pharmacy technicians and the evolving role of these technicians in the modern pharmacy.

The FDA has approved dasatinib (Sprycel, Briston-Myers Squibb) tablets in combination with chemotherapy for the treatment of pediatric patients ≥1 year of age with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

Everything pharmacists should know about gene therapy medications from current approved products to near and long-term pipeline information.

Study results show a genetic risk variant on astrocytes enhances the accessibility of the central nervous system (CNS) to peripheral immune cells, escalating the risk of autoimmune inflammation and multiple sclerosis.

Aurobindo Pharma USA is voluntarily recalling 80 lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP to the consumer level, due to the detection of trace amounts N-nitrosodiethylamine.

The guidelines recommend using molecular tests that deliver results in 15-60 minutes instead of rapid-influenza diagnostic tests (RIDTs), which produce quick results but can be falsely negative in at least 30% of outpatients with influenza.

This vaccine does not constitute a primary immunization series against pertussis.

Patients who transitioned to COT, which is defined as daily or near-daily use of opioids for at least 90 days, had total health care expenditures that were $4607 higher than those of patients who did not continue long-term opioid use.

The weekly report is also available through an online, interactive map, which allows anyone to search and find information regarding the most current state of influenza in their community.

Under the settlement and license agreement, Neos has granted Teva the right to manufacture and market its generic version of Cotempla XR-ODT® under the Teva ANDA beginning on July 1, 2026, or earlier under certain circumstances.

This is the only vaccination approved in the United States to prevent this bacterial disease.

We analyzed the data, and these are the articles our audience was most interested in reading online this year.

According to the indictment, from May 2014 to September 2016, the involved parties allegedly recieved kickbacks for the referral of TRICARE and DOL beneficiaries to obtain expensive compound drugs.

Opioids were involved in over two-thirds of overdose deaths in 2017.

Many residency positions draw hundreds of applicants for a single opening.

The FDA has approved tagraxofusp-erzs (Elzonris, Stemline Therapeutics) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, aged 2 years and older.

Ravulizumab (Ultomiris, Alexion) is the first long-acting complement inhibitor approved for the treatment of paroxysmal nocturnal hemoglobinura.

Cigna recently announced the completion of its $54-billion acquisition of Express Scripts.

The FDA has approved calaspargase pegol-mknl (Asparlas, Servier Pharmaceuticals) as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Swisslog Healthcare's Relay, which will deliver medications and supplies, has the potential to assist staff members with daily tasks and deter drug diversion.